1. |
Santegoets SJ, van den Eertwegh AJ, van de Loosdrecht AA, et al. Human dendritic cell line models for DC differentiation and clinical DC vaccination studies [J]. J Leukoc Biol, 2008; 84(6): 13641373.
|
2. |
Kim HS, Choo YS, Koo T, et al. Enhancement of antitumor immunity of dendritic cells pulsed with heattreated tumor lysate in murine pancreatic cancer [J]. Immunol Lett, 2006; 103(2): 142148.
|
3. |
Xia Y, Dai J, Lu PR, et al. Distinct effect of CD40 and TNFsignaling on the chemokine/chemokine receptor expression and function of the human monocytederived dendritic cells [J]. Cell Mole Immunol, 2008; 5(2): 4656.
|
4. |
Ishimoto H, Yanagihara K, Araki N, et al. Singlecell observation of phagocytosis by human blood dendritic cells [J]. Jpn J Infect Dis, 2008; 61(4): 294297.
|
5. |
Koido S, Hara E, Homma S, et al. Cancer vaccine by fusions of dendritic and cancer cells [J].Clin Dev Immunol, 2009; 2009: ID657369. doi: 10.1155/2009/657369.
|
6. |
Huang CF, Monie A, Weng WH, et al. DNA vaccines for cervical cancer [J]. Am J Transl Res, 2010; 2(1): 7587.
|
7. |
薛刚, 曹永宽, 王培红, 等. 肿瘤细胞裂解物致敏的树突状细胞对结肠癌LoVo细胞的杀伤作用 [J]. 中国普外基础与临床杂志, 2009; 16(1): 4851.
|
8. |
谭广, 任金帅, 王忠裕, 等. TNFα增强树突状细胞诱导的抗胰腺癌免疫应答的实验研究 [J]. 中国普外基础与临床杂志, 2006; 13(6): 689692.
|
9. |
Lee DH. Dendritic cellsbased vaccine and immune monitoring for hepatocellular carcinoma [J]. Korean J Physiol Pharmacol, 2010; 14(1): 1114.
|
10. |
Srivastava PK. Therapeutic cancer vaccines [J]. Curr Opin Immunol, 2006; 18(2): 201205.
|
11. |
Kikuchi T. Genetically modified dendritic cells for therapeutic immunity [J]. Tohoku J Exp Med, 2006; 208(1): 18.
|
12. |
Recktenwald CV, Kellner R, Lichtenfels R, et al. Altered detoxification status and increased resistance to oxidative stress by Kras transformation [J]. Cancer Res, 2008; 68(24): 1008610093.
|
13. |
Shen YM, Yang XC, Yang C, et al. Enhanced therapeutic effects for human pancreatic cancer by application Kras and IGFIR antisense oligodeoxynucleotides [J]. World J Gastroenterol, 2008; 14(33): 51765185.
|
14. |
Lee SH, Lee SJ, Jung YS, et al. Blocking of p53Snail binding, promoted by oncogenic KRas, recovers p53 expression and function [J]. Neoplasia, 2009; 11(1): 2231.
|
15. |
杨波, 何杨, 孙冬林, 等. Kras(12Val)树突状细胞疫苗诱导抗胰腺癌免疫反应 [J]. 苏州大学学报(医学版), 2007; 27(5): 691700.
|
16. |
Wang YX, Gao L, Ji ZZ. Inhibitary effects of antisense oligonucleotide specific to Kras point mutation on the target gene expression in human pancreatic carcinoma cells [J]. Chin Med J (Engl), 2007; 120(16): 14481450.
|
17. |
Biragyn A, Ruffini PA, Coscia M, et al. Chemokine receptormediated delivery directs selftumor antigen efficiently into the class Ⅱ processing pathway in vitro and induces protective immunity in vivo [J]. Blood, 2004; 104(7): 19611969.
|
18. |
Bertho N, Adamski H, Toujas L, et al. Efficient migration of dendritic cells toward lymph node chemokines and induction of T(H)1 responses require maturation stimulus and apoptotic cell interaction [J]. Blood, 2005; 106(5): 17341741.
|
19. |
Trinchieri G. Interleukin12 and the regulation of innate resistance and adaptive immunity [J]. Nat Rev Immunol, 2003; 3(2): 133146.
|
20. |
Brivio F, Lissoni P, Rovelli F, et al. Effects of IL2 preoperative immunotherapy on surgeryinduced changes in angiogenic regulation and its prevention of VEGF increase and IL12 decline [J]. Hepatogastroenterology, 2002; 49(44): 385387.
|
21. |
Pietil TE, Veckman V, Lehtonen A, et al. Multiple NFkappaB and IFN regulatory factor family transcription factors regulate CCL19 gene expression in human monocytederived dendritic cells [J]. J Immunol, 2007; 178(1): 253261.
|
22. |
Nakano H, Lin KL, Yanagita M, et al. Bloodderived inflammatory dendritic cells in lymph nodes stimulate acute TH1 immune responses [J]. Nat Immunol, 2009; 10(4): 394402.
|
23. |
Britschgi MR, Link A, Lissandrin TK, et al. Dynamic modulation of CCR7 expression and function on naive T lymphocytes in vivo [J]. J Immunol, 2008; 181(11): 76817688.
|
24. |
李立, 张升宁, 冉江华, 等. 受体来源未成熟树突状细胞诱导大鼠肝移植免疫低反应性的实验研究 [J]. 中国普外基础与临床杂志, 2009; 16(1): 3238.
|
25. |
Yamashita U, Kuroda E. Regulation of macrophagederived chemokine (MDC, CCL22) production [J]. Crit Rev Immunol, 2002; 22(2): 105114.
|
26. |
Gobert M, Treilleux I, BendrissVermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome [J]. Cancer Res, 2009; 69(5): 20002009.
|
27. |
Mailloux AW, Young MR. NKdependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment [J]. J Immunol, 2009; 182(5): 27532765.
|
28. |
AlAlwan MM, Rowden G, Lee TD, et al. Fascin is involved in the antigen presentation activity of mature dendritic cells [J]. J Immunol, 2001; 166(1): 338345.
|
29. |
Geyeregger R, Zeyda M, Bauer W, et al. Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actinbundling protein fascin [J]. Blood, 2007; 109(10): 42884295.
|
30. |
Zanet J, Payre F, Plaza S. Fascin for cell migration in Drosophila [J]. Fly (Austin), 2009; 3(4): 281282.
|
31. |
Hashimoto Y, Loftis DW, Adams JC. Fascin1 promoter activity is regulated by CREB and the aryl hydrocarbon receptor in human carcinoma cells [J]. PLoS One, 2009; 4(4): e5130.
|